Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of VCT220 tablets in adults with overweight or obesity
CTR20244365Phase 3Completed
- Sponsor
- Vinnerna Pharmaceutical
- Start
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of VCT220 in obesity, Overweight, sponsored by Vinnerna Pharmaceutical. Started Dec 2024; status: completed.
02
Drugs
VCT220
03
Conditions
obesityOverweight
Beyond the preview
Go deeper on CTR20244365.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20244365.